Novartis Unveils Zero Profit COVID-19 Drugs Portfolio
Dexamethasone On List For Low-Income Countries
Lutz Hegemann, chief operating officer for global health at Novartis, tells Scrip the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.
You may also be interested in...
While the traditional players such as Pfizer and GSK, as well as newcomer AstraZeneca, are hot in pursuit of a COVID-19 vaccine, the Swiss major is sticking to drugs, the area where "we do have deep expertise," CEO Vas Narasimhan told journalists.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.